
Bryant England on advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
-
Narrated by:
-
By:
About this listen
Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.
Read the full article:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
No reviews yet